These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 11545631

  • 1. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma).
    Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF.
    Arch Ophthalmol; 2001 Sep; 119(9):1269-72. PubMed ID: 11545631
    [Abstract] [Full Text] [Related]

  • 2. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
    Shields CL, Shelil A, Cater J, Meadows AT, Shields JA.
    Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
    [Abstract] [Full Text] [Related]

  • 3. Chemoreduction for unilateral retinoblastoma.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ.
    Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
    [Abstract] [Full Text] [Related]

  • 4. Chemoreduction for retinoblastoma.
    Moll AC, Imhof SM, Schouten-van Meeteren AY, Boers M, van Leeuwen F, Hofman P.
    Arch Ophthalmol; 2003 Oct; 121(10):1513. PubMed ID: 14557204
    [No Abstract] [Full Text] [Related]

  • 5. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, Shields JA.
    Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
    [Abstract] [Full Text] [Related]

  • 6. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
    Demirci H, Eagle RC, Shields CL, Shields JA.
    Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
    [Abstract] [Full Text] [Related]

  • 7. Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
    Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH.
    Pediatr Blood Cancer; 2010 Mar; 54(3):384-7. PubMed ID: 19908299
    [Abstract] [Full Text] [Related]

  • 8. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
    Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ.
    Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
    [Abstract] [Full Text] [Related]

  • 9. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
    Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO.
    Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
    [Abstract] [Full Text] [Related]

  • 10. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
    Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, Meadows AT.
    Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
    [Abstract] [Full Text] [Related]

  • 11. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ.
    Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
    [Abstract] [Full Text] [Related]

  • 12. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
    Gündüz K, Shields CL, Shields JA, Meadows AT, Gross N, Cater J, Needle M.
    Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790
    [Abstract] [Full Text] [Related]

  • 13. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA.
    Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
    [Abstract] [Full Text] [Related]

  • 14. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA.
    Trans Am Ophthalmol Soc; 2004 Sep; 102():35-44; discussion 44-5. PubMed ID: 15747743
    [Abstract] [Full Text] [Related]

  • 15. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
    Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, Shields JA.
    Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
    [Abstract] [Full Text] [Related]

  • 16. Multifaceted chemotherapy for trilateral retinoblastoma.
    Dimaras H, Héon E, Doyle J, Strahlendorf C, Paton KE, Halliday W, Babyn P, Gallie BL, Chan HS.
    Arch Ophthalmol; 2011 Mar; 129(3):362-5. PubMed ID: 21402997
    [No Abstract] [Full Text] [Related]

  • 17. Residual intraretinal retinoblastoma after chemoreduction failure.
    Hwang CK, Aaberg TM, Chevez-Barrios P, Verner-Cole E, Gombos DS, Paysse E, Chintagumpala M, Gao W, Grossniklaus HE.
    Arch Ophthalmol; 2012 Feb; 130(2):246-8. PubMed ID: 22332223
    [No Abstract] [Full Text] [Related]

  • 18. Regarding chemoreduction for retinoblastoma and intracranial neoplasms.
    Meadows AT, Shields CL.
    Arch Ophthalmol; 2004 Oct; 122(10):1570-1; author reply 1571. PubMed ID: 15477483
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.